A New Collaboration Supporting CABSI Prevention

According to the CDC, Catheter-associated bloodstream infections (CABSIs) are among the most serious healthcare-associated risks in the United States. Preventing these infections requires consistent protection—from skin and site antisepsis during line insertion to antimicrobial protection at the catheter site.

PDI has entered into an exclusive commercial collaboration with Johnson & Johnson MedTech to represent BioPatch™ Protective Disk with CHG. Together with PDI’s Prevantics® product portfolio, healthcare teams now have access to an integrated approach to catheter-associated infection prevention supported by extensive clinical evidence.

• Prevantics^® Portfolio – CHG + IPA antisepsis designed to simplify skin antisepsis and support scrub-the-hub compliance.
• BioPatch^™ Protective Disk with CHG – Continuous antimicrobial protection delivering 360° chlorhexidine coverage around the catheter insertion site.

Through this collaboration, healthcare organizations gain access to coordinated field support, clinical education, and protocol guidance throughout the catheter dwell time—helping clinicians implement best practices to protect patients and reduce infection risk.